Ruthenium(III) complexes are promising anticancer metallodrugs because of their antimetastatic (migrastatic) potential and significantly lower host toxicity than generally used platinum metallodrugs. On the other hand, the ruthenium(III) complexes generally show low solubility and stability in an aqueous environment but exhibit some toxicity associated with unspecific delivery. For these reasons, numerous ongoing studies deal with their encapsulation into various delivery systems to maximize their therapeutic efficacy. One of these systems can also be crystals of nontoxic metal-organic frameworks (MOFs). In this work, we studied incorporation of a bioactive ruthenium(III) complex (RuC) inside MOFs derived from γ-cyclodextrin (γ-CD) and biocompatible potassium ions, forming CD-MOF-1. Viability studies in vitro were carried out using spheroids of human hepatoblastoma cell line HepG2. These studies revealed that the RuC-CD-MOF-1 system provides effective cancer cell suppression through slow gradual release over a longer period (>10 days) while reducing acute cytotoxic effects associated with naked RuC. This combination was defined for further development and optimization as a drug-delivery platform for metallodrugs.

• MeSH
• Hep G2 Cells MeSH
• Cyclodextrins * chemistry   MeSH
• gamma-Cyclodextrins * chemistry   MeSH
• Coordination Complexes * chemistry   pharmacology   chemical synthesis   MeSH
• Humans MeSH
• Molecular Structure MeSH
• Metal-Organic Frameworks * chemistry   pharmacology   chemical synthesis   MeSH
• Cell Proliferation drug effects   MeSH
• Antineoplastic Agents * pharmacology   chemistry   chemical synthesis   MeSH
• Ruthenium * chemistry   pharmacology   MeSH
• Drug Screening Assays, Antitumor MeSH
• Cell Survival drug effects   MeSH
• Check Tag
• Humans MeSH
• Publication type
• Journal Article MeSH
• Names of Substances
• Cyclodextrins * MeSH
• gamma-Cyclodextrins * MeSH
• Coordination Complexes * MeSH
• Metal-Organic Frameworks * MeSH
• Antineoplastic Agents * MeSH
• Ruthenium * MeSH